Last checked at 8 Oct 2018 14:00
hVIVO PLC
("hVIVO" or the "Company")
Director's Dealings
London, UK, 8 October 2018: hVIVO plc (AIM: HVO), an industry leading clinical development services business pioneering human disease models based upon viral and allergen challenge, announces that application has been made to AIM for the admission of 6,420 new ordinary shares of 5.0p each in the Company (the "New Ordinary Shares").
The New Ordinary Shares have been allotted pursuant to the purchase by Jim Winschel (Non-Executive Director) of new ordinary shares, under the terms of his letter of appointment as set out in the Company's announcement of 4 November 2014 which stated that Mr Winschel had entered into a binding commitment to purchase £4,000 of hVIVO plc new ordinary shares per quarter.
The New Ordinary Shares represent Mr Winschel's investment for the quarter ended 30 September 2018. On 8 October 2018, Mr Winschel invested in an additional 6,420 ordinary shares, at a price of 62.3 pence per share.
Following admission of the New Ordinary Shares to trading on AIM, the total number of ordinary shares with voting rights in issue will be 80,581,494 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.
Admission of the New Ordinary Shares ("Admission"), which will rank pari passu in all respects with the Company's existing shares in issue, is expected to occur on 12 October 2018. Following Admission, Mr Winschel will be interested in a total of 79,558 ordinary shares of 5.0p in the Company, representing 0.1% of the Company's issued share capital.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail:
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1 | Details of the persons discharging managerial responsibilities/persons closely associated | |||||||
a) | Name | Jim Winschel | ||||||
2 | Reason for the notification | |||||||
a) | Position/ status | Non-Executive Director | ||||||
b) | Initial notification/ Amendment | Initial Notification | ||||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
a) | Name | hVIVO plc | ||||||
b) | Legal Entity Identifier | N/A | ||||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
a) | Description of the financial instrument, type of instrument
Identification code | Ordinary shares of 5 pence each
GB00B6ZM0X53 | ||||||
b) | Nature of the transaction | Acquisition of ordinary shares | ||||||
c) | Currency | GBP | ||||||
d) | Price(s) and volume(s) |
| ||||||
| ||||||||
e) | Aggregated information - Aggregated volume - Price - Aggregated total |
6,420 62.3p £3,999.66 | ||||||
f) | Date of the transaction | 8 October 2018 | ||||||
g) | Place of the transaction | London Stock Exchange, AIM | ||||||
For further information please contact:
hVIVO plc |
|
Trevor Phillips (Executive Chairman) | +44 207 756 1300 |
Fleur Wood (Director, Investor Relations)
|
|
Numis Securities Limited | +44 207 260 1000 |
Michael Meade / Freddie Barnfield (Nominated Adviser) |
|
James Black / Michael Burke (Corporate Broking) |
|
|
|
FTI Consulting |
|
Simon Conway / Victoria Foster Mitchell | +44 203 727 1000 |
Notes to Editors:
hVIVO plc ("hVIVO") is pioneering a human-based clinical trial platform to accelerate drug and vaccine development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV, HRV and respiratory indications, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies and inoculated over 2500 volunteers.